Direct Treatment Costs of Neovascular Age-related Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditure

Basit Öğe Kaydı
dc.contributor.authorYildirim, Seyda
dc.contributor.authorAkkin, Cezmi
dc.contributor.authorOztas, Zafer
dc.contributor.authorNalcaci, Serhad
dc.contributor.authorAfrashi, Filiz
dc.contributor.authorMentes, Jale
dc.date.accessioned2019-10-27T10:42:56Z
dc.date.available2019-10-27T10:42:56Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives: The aim was to quantify the direct medical cost of neovascular age-related macular degeneration (AMD) versus gained or preserved vision. Materials and Methods: Data of patients treated for neovascular AMD between January 2009 to January 2014 were reviewed. Patients with complete follow-up for two years, treated with only intravitreal ranibizumab injections and with no intraocular surgery were included. Demographics, diagnostic investigations, the number of visits and injections, changes in visual acuity (VA) at one year and two years from baseline were noted. Total cost was calculated for the first and second years, and the cost of improving or preserving initial vision level was determined with subgroup analysis. Results: Two-hundred eyes of 175 patients (86 male and 89 female) with a mean age of 72.3 +/- 7.8 years were included. Mean VA was 0.67 logMAR at baseline, 0.60 logMAR at the end of the first year, and 0.67 logMAR at the end of the second year. At the end of the 2 years, VA increased in 82 eyes (41%), remained the same in 42 eyes (21%), and decreased in 76 eyes (38%). The mean number of visits in the first and second years were 6.56 (3-12) and 5.74 (3-10), respectively. An average of 4.42 (1-8) injections were performed in the first year and 2.25 (0-7) in the second. The total direct medical cost for AMD was 9,628 TL (Turkish Lira) per patient for 2 years, which consisted of 529 TL in visit costs, 115 TL in fluorescein and indocyanine angiography costs, 611 TL in injection procedure costs, and 8,371 TL in drug costs. The cost of one line of VA gain was 11,911 TL in the first year. Conclusion: This study showed that treatment increased or stabilized vision in a reasonable proportion of patients, that cost of management decreases in the second year, and that drug expenses are the leading item in reimbursement.en_US
dc.identifier.doi10.4274/tjo.44370
dc.identifier.endpage32en_US
dc.identifier.issn1300-0659
dc.identifier.issn2147-2661
dc.identifier.issue1en_US
dc.identifier.pmid29576895en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.4274/tjo.44370
dc.identifier.urihttps://hdl.handle.net/11454/30700
dc.identifier.volume48en_US
dc.identifier.wosWOS:000429421300007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Ophthalmological Socen_US
dc.relation.ispartofTurk Oftalmoloji Dergisi-Turkish Journal of Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAge-related macular degenerationen_US
dc.subjectdirect medical costen_US
dc.subjectranibizumaben_US
dc.titleDirect Treatment Costs of Neovascular Age-related Macular Degeneration and Comparison of Gained and/or Preserved Vision with Expenditureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu